A first-in-human study of ANN-002 in treatment of hereditary angioedema
Phase of Trial: Phase I/II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs ANN 002 (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; First in man
- 08 Nov 2017 According to an Adverum Biotechnologies media release, the Company also plans to file an IND application with the FDA in the second half of 2018.
- 13 May 2016 According to an Avalanche Biotechnologies media release, this trial is expected to initiate in 2017.
- 13 May 2016 New trial record